BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 34775984)

  • 1. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients.
    Rahimi P; Tarharoudi R; Rahimpour A; Mosayebi Amroabadi J; Ahmadi I; Anvari E; Siadat SD; Aghasadeghi M; Fateh A
    Virol J; 2021 Nov; 18(1):221. PubMed ID: 34775984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
    Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
    Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
    BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.
    Jalilian S; Latifi SM; Makvandi M; Teimoori A; Azaran A; Parsanahad M; Kayedani G
    Indian J Med Microbiol; 2017; 35(2):262-268. PubMed ID: 28681817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNL3/4 polymorphisms as a two-edged sword: An association with COVID-19 outcome.
    Matic S; Milovanovic D; Mijailovic Z; Djurdjevic P; Sazdanovic P; Stefanovic S; Todorovic D; Popovic S; Vitosevic K; Vukicevic V; Vukic M; Vukovic N; Milivojevic N; Zivanovic M; Jakovljevic V; Filipovic N; Baskic D; Djordjevic N
    J Med Virol; 2023 Feb; 95(2):e28506. PubMed ID: 36655749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
    Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
    PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.
    Wróblewska A; Bernat A; Woziwodzka A; Markiewicz J; Romanowski T; Bielawski KP; Smiatacz T; Sikorska K
    Clin Exp Med; 2017 May; 17(2):225-232. PubMed ID: 27125837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between
    Agwa SHA; Kamel MM; Elghazaly H; Abd Elsamee AM; Hafez H; Girgis SA; Ezz Elarab H; Ebeid FSE; Sayed SM; Sherif L; Matboli M
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
    Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
    J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Its all about IFN-λ4: Protective role of IFNL4 polymorphism against COVID-19-related pneumonia in females.
    Matic S; Milovanovic D; Mijailovic Z; Djurdjevic P; Sazdanovic P; Stefanovic S; Todorovic D; Popovic S; Vitosevic K; Vukicevic V; Vukic M; Vukovic N; Milivojevic N; Zivanovic M; Jakovljevic V; Filipovic N; Djordjevic N; Baskic D
    J Med Virol; 2023 Oct; 95(10):e29152. PubMed ID: 37812032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians.
    Knapp S; Zakaria Z; Hashem M; Zaghla H; Khakoo SI; Waked I; Thursz M; Abdelwahab SF
    Hepatol Int; 2015 Apr; 9(2):251-7. PubMed ID: 25788203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.
    Asnavandi M; Zargar M; Vaziri F; Jamnani FR; Gharibzadeh S; Fateh A; Siadat SD
    Genes Immun; 2017 Sep; 18(3):144-151. PubMed ID: 28703131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
    Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
    J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.
    Indolfi G; Azzari C; Resti M
    World J Gastroenterol; 2014 Jul; 20(28):9245-52. PubMed ID: 25071317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
    Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Interferon Lambda 3 and 4 Gene SNPs and Their Expression with COVID-19 Disease Severity: A Cross-Sectional Study.
    Zahid W; Farooqui N; Zahid N; Ahmed K; Anwar MF; Rizwan-Ul-Hasan S; Hussain AR; Sarría-Santamera A; Abidi SH
    Infect Drug Resist; 2023; 16():6619-6628. PubMed ID: 37840831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
    J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.